Clinical Trials Logo

Clinical Trial Summary

A multi-center, open-label, single ascending dose study to enroll opioid dependent treatment-seeking subjects. Subjects to be enrolled into 3 cohorts receiving low, medium and high doses of depot buprenorphine. A fourth cohort will be enrolled to evaluate the PK of RBP-6000 after receiving suboxone tablets for 7 days.


Clinical Trial Description

All subjects will undergo screening period of up to 7 days. Eligible subjects in Cohorts 1-3 will receive RBP-6000 doses on at the conclusion of screening. Subjects in Cohort 4 will receive sublingual (SL) Suboxone for 7 days prior to receiving an injection of RBP-6000.

For all cohorts, subjects will be admitted to the clinic 2 days prior to beginning any dosing, and will remain in the clinic through Day 21. Blood collection for hematology, chemistry and serology analysis will be drawn at screening, and intermittently for safety assessments during the study period. Subjects in Cohorts 1-3 will have a PK sample collected pre-dose and serial PK collection post-dosing. Subjects in Cohort 4 will have daily PK collections while admitted during Suboxone dosing and serially after RBP-6000 administration.

Subjects will return to the clinic for PK sample collection through Day 140 or until buprenorphine concentrations fall below 100 pg/mL. Subjects will return to the clinic for safety assessments through Day 150.

Subjects experiencing signs and symptoms of withdrawal prior to RBP-6000 during the residential phase may receive non-opioid rescue medications. Subjects who experience signs and symptoms of withdrawal may receive hydromorphone beginning on Day 11 if necessary. Methadone dosing can begin, if clinically indicated, on Day 16 only for subjects who have not been administered hydromorphone. Subjects will not be allowed to use buprenorphine at any time during the study.

Subjects will also receive psychosocial and behavioral counseling as specified by the PI. The End of Study visit will occur 1 week after Day 84 or 1 week after the monthly follow-up visits after Day 84, given a subject's buprenorphine plasma concentration has fallen below 100 pg/mL. For subjects with plasma concentrations of buprenorphine above 100 pg/mL at Day 140, Day 150 will be the End of Study visit.

Subjects will not be enrolled into the next cohort until safety data for at least the first 6 subjects has been reviewed. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT03002961
Study type Interventional
Source Indivior Inc.
Contact
Status Completed
Phase Phase 1
Start date July 2012
Completion date October 2013

See also
  Status Clinical Trial Phase
Completed NCT02440256 - Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02559973 - Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder Phase 1
Suspended NCT04577144 - An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery-Long Term
Not yet recruiting NCT04946656 - A Study of SPG Block for Opioid Withdrawal Early Phase 1
Completed NCT03033732 - A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse Phase 4
Recruiting NCT03821337 - Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Improve Functioning N/A
Recruiting NCT04375033 - A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder Phase 4
Completed NCT02942199 - MySafeRx & MedicaSafe Open-Label Buprenorphine Induction and Lapse Evaluation (MyMOBILE) N/A
Completed NCT02672111 - Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder Phase 3
Completed NCT02044094 - Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder Phase 2
Completed NCT02765867 - Single-dose, Study of RBP-6000 in Opioid Dependent Individuals Phase 1
Recruiting NCT04567784 - Neuroimaging and CBD for Heroin Use Disorder Phase 2
Recruiting NCT04238754 - Oral Cannabidiol for Opioid Withdrawal Phase 1/Phase 2
Completed NCT03944850 - Computerized Anxiety Sensitivity Treatment for Opioid Use Disorders N/A
Completed NCT03248947 - Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075 Early Phase 1
Active, not recruiting NCT02778282 - MySafeRxâ„¢: An Integrated Mobile Platform for Buprenorphine Adherence N/A
Completed NCT04448561 - A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants Phase 1
Completed NCT04447287 - A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder Phase 1
Not yet recruiting NCT04920864 - rTMS, Stress and Opioid Use Disorder N/A